{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:30:49Z","timestamp":1773275449480,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Science","award":["30700185"],"award-info":[{"award-number":["30700185"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.clon.2010.05.005","type":"journal-article","created":{"date-parts":[[2010,6,20]],"date-time":"2010-06-20T20:53:59Z","timestamp":1277067239000},"page":"438-447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Management of Differentiated Thyroid Cancer with Rising Thyroglobulin and Negative Diagnostic Radioiodine Whole Body Scan"],"prefix":"10.1016","volume":"22","author":[{"given":"M.","family":"Chao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2010.05.005_bib1","first-page":"98","article-title":"Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer","volume":"79","author":"Ozata","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clon.2010.05.005_bib2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0300-9084(99)80096-0","article-title":"Serum and tissue thyroglobulin measurement: clinical applications in thyroid disease","volume":"81","author":"Pacini","year":"1999","journal-title":"Biochimie"},{"key":"10.1016\/j.clon.2010.05.005_bib3","first-page":"1473","article-title":"The possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scan","volume":"46","author":"Chao","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clon.2010.05.005_bib4","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1210\/jc.2007-2357","article-title":"Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer","volume":"93","author":"Kloos","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clon.2010.05.005_bib5","article-title":"Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases","volume":"1","author":"Chao","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clon.2010.05.005_bib6","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1046\/j.1365-2265.2003.01733.x","article-title":"Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study","volume":"58","author":"Koh","year":"2003","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.clon.2010.05.005_bib7","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1210\/jcem.86.9.7831","article-title":"Outcome of differentiated thyroid cancer with detectable serum Tg and negative 131I whole body scan: comparison of patients treated with high 131I activities versus untreated patients","volume":"86","author":"Pacini","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clon.2010.05.005_bib8","first-page":"27","article-title":"Evaluation of 131I therapy for differentiated thyroid carcinoma patients with elevated Tg and negative 131I whole body scan","volume":"23","author":"Tian","year":"2003","journal-title":"Chin J Nucl Med"},{"key":"10.1016\/j.clon.2010.05.005_bib9","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s002590000443","article-title":"Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin","volume":"28","author":"De Keizer","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.clon.2010.05.005_bib10","first-page":"1488","article-title":"Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan","volume":"80","author":"Pineda","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clon.2010.05.005_bib11","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1210\/jcem.86.4.7407","article-title":"Current approaches to primary therapy for papillary and follicular thyroid cancer","volume":"86","author":"Mazzaferri","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clon.2010.05.005_bib12","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1530\/eje.0.1480589","article-title":"Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin","volume":"148","author":"Van Tol","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.clon.2010.05.005_bib13","first-page":"1888","article-title":"Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels","volume":"28","author":"Pacini","year":"1987","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clon.2010.05.005_bib14","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1007\/s00259-004-1516-y","article-title":"Treatment of iodine-negative thyroglobulin-positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases","volume":"31","author":"Kabasakal","year":"2004","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.clon.2010.05.005_bib15","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1210\/jcem.87.4.8373","article-title":"Lack of impact of radioiodine therapy in Tg-positive, diagnostic whole-body scan-negative patients with follicular cell derived thyroid cancer","volume":"87","author":"Fatourechi","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clon.2010.05.005_bib16","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1530\/eje.0.1370254","article-title":"Evaluation and treatment of persistent thyroglobulinemia in patients with well-differentiated thyroid cancer","volume":"137","author":"Pachucki","year":"1997","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.clon.2010.05.005_bib17","first-page":"1766","article-title":"Can iodine-131 whole-body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma?","volume":"31","author":"Ronga","year":"1990","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clon.2010.05.005_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1046\/j.1365-2265.2002.01574.x","article-title":"Does radioiodine therapy have disadvantageous effects in non-iodine accumulating differentiated thyroid carcinoma?","volume":"57","author":"Schaap","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.clon.2010.05.005_bib19","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1590\/S0004-27302005000200011","volume":"49","author":"Ros\u00e1rio","year":"2005","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"10.1016\/j.clon.2010.05.005_bib20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/00006231-200607000-00004","article-title":"Efficacy of radioiodine therapy in the treatment of elevated serum thyroglobulin in patients with differentiated thyroid carcinoma and negative whole-body iodine scan","volume":"27","author":"Saghari","year":"2006","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.clon.2010.05.005_bib21","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/BF03347243","article-title":"Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer","volume":"28","author":"Alzahrani","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.clon.2010.05.005_bib22","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1157\/13102483","article-title":"Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course","volume":"26","author":"Guti\u00e9rrez Cardo","year":"2007","journal-title":"Rev Esp Med Nucl"},{"key":"10.1016\/j.clon.2010.05.005_bib23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00259-005-1929-2","article-title":"Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment","volume":"33","author":"Pace","year":"2006","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.clon.2010.05.005_bib24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF03346465","article-title":"Thyrotropin variations may explain some positive radioiodine therapy scans in patients with negative diagnostic scans","volume":"32","author":"Zanotti-Fregonara","year":"2009","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.clon.2010.05.005_bib25","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2010.05.005_bib26","first-page":"1164","article-title":"Is blind 131I therapy justified for patients with negative Tg and positive 131I WBS?","volume":"46","author":"Ma","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clon.2010.05.005_bib27","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1210\/jc.2002-021702","article-title":"A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma","volume":"88","author":"Mazzaferri","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clon.2010.05.005_bib28","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1530\/eje.0.1510539","article-title":"Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice","volume":"151","author":"Schlumberger","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.clon.2010.05.005_bib29","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM199801293380506","article-title":"Papillary and follicular thyroid carcinoma","volume":"338","author":"Schlumberger","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clon.2010.05.005_bib30","first-page":"1790","article-title":"Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays","volume":"29","author":"Schlumberger","year":"1988","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clon.2010.05.005_bib31","first-page":"98","article-title":"Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer","volume":"79","author":"Ozata","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clon.2010.05.005_bib32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1210\/jcem.85.1.6310","article-title":"Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?","volume":"85","author":"Cailleux","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clon.2010.05.005_bib33","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1210\/jcem.87.4.8274","article-title":"Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment","volume":"87","author":"Pacini","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clon.2010.05.005_bib34","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1210\/jcem.87.7.8702","article-title":"Is the serum thyroglobulin response to recombinant human TSH sufficient, by itself, to monitor for residual thyroid carcinoma?","volume":"87","author":"Robbins","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clon.2010.05.005_bib35","first-page":"3877","article-title":"A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer","volume":"84","author":"Haugen","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clon.2010.05.005_bib36","first-page":"1470","article-title":"Serum thyroglobulin concentrations and (131)I whole body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone","volume":"42","author":"David","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clon.2010.05.005_bib37","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.0300-0664.2001.01425.x","article-title":"The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre","volume":"56","author":"Vitale","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.clon.2010.05.005_bib38","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1210\/jcem.87.4.8338","article-title":"Is diagnostic iodine-131 scanning with recombinant human TSH (rhTSH) useful in the follow-up of differentiated thyroid cancer after thyroid ablation?","volume":"87","author":"Mazzaferri","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clon.2010.05.005_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/105072502753451959","article-title":"Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin","volume":"12","author":"Haugen","year":"2002","journal-title":"Thyroid"},{"key":"10.1016\/j.clon.2010.05.005_bib40","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1210\/jcem.86.12.8065","article-title":"Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma","volume":"86","author":"Pacini","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clon.2010.05.005_bib41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/105072502320288438","article-title":"Management of low risk well differentiated thyroid cancer based only upon thyroglobulin measurement after recombinant human thyrotropin. The rhTSH-stimulated thyroglobulin Study Group","volume":"12","author":"Wartofsky","year":"2002","journal-title":"Thyroid"},{"key":"10.1016\/j.clon.2010.05.005_bib42","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00259-006-0276-2","article-title":"Combined PET\/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality?","volume":"34","author":"Zoller","year":"2007","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.clon.2010.05.005_bib43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejrad.2007.12.004","article-title":"Clinical implication of F-18 FDG PET\/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin","volume":"70","author":"Kim","year":"2009","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.clon.2010.05.005_bib44","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1089\/105072502760043459","article-title":"Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation","volume":"12","author":"van Tol","year":"2002","journal-title":"Thyroid"},{"key":"10.1016\/j.clon.2010.05.005_bib45","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/MNM.0b013e32832dcfa7","article-title":"Value of 18F-FDG-PET\/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis","volume":"30","author":"Dong","year":"2009","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.clon.2010.05.005_bib46","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00259-001-0745-6","article-title":"Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma","volume":"29","author":"Petrich","year":"2002","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.clon.2010.05.005_bib47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1210\/jc.2003-031027","article-title":"Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma","volume":"89","author":"Chin","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clon.2010.05.005_bib48","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s002590050493","article-title":"Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study","volume":"26","author":"Grunwald","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.clon.2010.05.005_bib49","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jcem.84.7.5827","article-title":"[18F]-2-fluoro-2-deoxyglucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels","volume":"84","author":"Wang","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clon.2010.05.005_bib50","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0889-8529(18)30319-0","article-title":"Ablative radioactive iodine therapy for apparently localized thyroid carcinoma. A decision analytic perspective","volume":"19","author":"Wong","year":"1990","journal-title":"Endocrinol Metab Clin N Am"},{"key":"10.1016\/j.clon.2010.05.005_bib51","series-title":"Practical management of thyroid cancer \u2013 A multidisciplinary approach","article-title":"Management of differentiated thyriod carcinoma patients with negative whole-body radioiodine scans and elevated serum thyroglobulin levels","author":"Mazzaferri","year":"2006"},{"key":"10.1016\/j.clon.2010.05.005_bib52","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/thy.2009.0110","article-title":"Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer","volume":"19","author":"Cooper","year":"2009","journal-title":"Thyroid"},{"key":"10.1016\/j.clon.2010.05.005_bib53","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1210\/jc.2009-1567","article-title":"Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan","volume":"95","author":"Kim","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clon.2010.05.005_bib54","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/00006231-200409000-00003","article-title":"Current issues in the management of differentiated thyroid cancer","volume":"25","author":"Mallick","year":"2004","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.clon.2010.05.005_bib55","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.clon.2010.04.008","article-title":"Molecular targeted therapies for patients with refractory thyroid cancer","volume":"22","author":"Schlumberger","year":"2010","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2010.05.005_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2010.05.019","article-title":"Thyroid cancer: evidence-based optimal management and the search for a cure","volume":"22","author":"Mallick","year":"2010","journal-title":"Clin Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655510001755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655510001755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:35:54Z","timestamp":1760542554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655510001755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0936655510001755"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2010.05.005","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Differentiated Thyroid Cancer with Rising Thyroglobulin and Negative Diagnostic Radioiodine Whole Body Scan","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2010.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}